Burning Rock Biotech (NASDAQ:BNR) Releases Earnings Results

Key Points

• Burning Rock Biotech reported a negative earnings per share (EPS) of ($0.15) for the quarter, reflecting significant financial challenges with a negative return on equity of 38.33% and a negative net margin of 45.41%.
• The stock is currently valued at $8.30, with a market capitalization of $89.25 million and a price-to-earnings (P/E) ratio of -4.39, indicating the company is operating at a loss.
• Burning Rock Biotech specializes in next-generation sequencing based cancer therapy selection tests, targeting various cancer types through tissue and liquid biopsy samples.

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, Zacks reports. Burning Rock Biotech had a negative return on equity of 38.33% and a negative net margin of 45.41%.

Burning Rock Biotech Stock Down 1.8%

NASDAQ:BNR opened at $8.30 on Monday. The company has a market cap of $89.25 million, a P/E ratio of -4.39 and a beta of 0.91. Burning Rock Biotech has a twelve month low of $2.18 and a twelve month high of $11.12. The business has a 50 day moving average price of $6.46 and a two-hundred day moving average price of $4.76.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.